体检人群血清M2型抗线粒体抗体流行率调查*

doi:10.3969/j.issn.1672-5069.2022.02.013

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (2): 203-206.doi: 10.3969/j.issn.1672-5069.2022.02.013

体检人群血清M2型抗线粒体抗体流行率调查^*

曲颖, 蔡晓波, 张启迪, 陆伦根

200080 上海市上海交通大学附属第一人民医院消化科

收稿日期:2021-06-16 出版日期:2022-03-10 发布日期:2022-03-15
通讯作者: 陆伦根,E-mail:lungenlu1965@163.com
作者简介:曲颖,女,37岁,医学博士,主治医师。主要从事脂肪肝和肝纤维化的基础与临床研究。E-mail: levine4959@163.com
基金资助:
*国家自然科学基金青年基金资助项目(编号81500463)

Prevalence of serum anti-mitochondrial antibody-M2 antibody in health check-up individuals

Qu Ying, Cai Xiaobo, Zhang Qidi, et al

Department of Gastroenterology, Shanghai General Hospital, JiaoTong University School of Medicine, Shanghai 200080, China

Received:2021-06-16 Online:2022-03-10 Published:2022-03-15

摘要/Abstract

摘要： 目的在健康体检人群中筛查原发性胆汁性胆管炎(PBC)的特异性抗体,即抗线粒体抗体(AMA)-M2,以了解其流行率。方法 2012年5月～2014年12月我院体检中心血清样本18515例,采用ELISA行AMA-M2定量检测,同时收集肝功能生化指标。结果在筛查的18515名体检者中,245例(1.3%)血清AMA-M2阳性,男性97名,女性148名,男女比例约为1:1.5,46～55岁年龄段阳性比例率为28.6%;12名AMA-M2阳性者同时伴有血清ALP水平升高,符合中国PBC诊断和治疗共识的诊断标准;54例高滴度AMA-M2抗体(＞150U/ml)者血清ALP为(92.8±85.6 U/L),GGT水平为(84.3±118.5 U/L,显著高于191例低滴度组【分别为(67.7±38.3U/L)和(39.1±61.8U/L),P<0.05】。结论健康体检人群血清AMA-M2抗体阳性并不少见,筛查AMA-M2抗体有助于早期识别PBC。

关键词: 原发性胆汁性胆管炎, 抗线粒体抗体, 筛查, 诊断

Abstract: Objective The purpose of this study was to investigate the prevalence of serum anti-mitochondrial antibody-M2 (AMA-M2) antibody in physical examination individuals. Methods 18515 serum samples were collected from the Physical Examination Center, Shanghai General Hospital between May 2012 and December 2014. Serum AMA-M2 was quantitatively detected by ELISA, and blood biochemical parameters were assayed. Results Among 18515 screened people, 245 persons (1.3%) were serum AMA-M2 positive, of which 97 were men and 148 were women, with the ratio of men to women of about 1∶1.5, and the highest positive rate (28.6%) was found in 46 to 55 year old age group(n=70); serum alkaline phosphatase levels increased in 12 persons with serum AMA-M2 positive, who met the diagnostic criteria of primary biliary cholangitis (PBC); serum ALP level in 54 persons with higher serum AMA-M2 (＞150U/ml) was (92.8±85.6 U/L), and serum GGT level was (84.3±118.5 U/L, significantly higher than [(67.7±38.3U/L) and (39.1±61.8U/L), respectively, P<0.05] in 191 individuals with low serum AMA-M2. Conclusion It is not uncommon that serum AMA-M2 antibody is positive in healthy people, and early screening serum AMA-M2 antibody is helpful for early diagnosis of PBC.

Key words: Primary biliary cholangitis, Anti-mitochondrial antibody, Physical examination and screening, Diagnosis

曲颖, 蔡晓波, 张启迪, 陆伦根. 体检人群血清M2型抗线粒体抗体流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(2): 203-206.

Qu Ying, Cai Xiaobo, Zhang Qidi, et al. Prevalence of serum anti-mitochondrial antibody-M2 antibody in health check-up individuals[J]. Journal of Practical Hepatology, 2022, 25(2): 203-206.

参考文献

[1] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015).中华肝脏病杂志,2016,24(1):5-13.
[2] Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. J Autoimmun, 2018,95:144-158.
[3] Tanaka A, Leung PS, Gershwin ME. Environmental basis of primary biliary cholangitis. Exp Biol Med (Maywood), 2018,243(2):184-189.
[4] Joshita S, Umemura T, Tanaka E,et al. Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. Clin J Gastroenterol, 2018,11(1):11-18.
[5] Galoosian A, Hanlon C, Zhang J, et al. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol, 2020, 8 (1):49-60.
[6] Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int, 2019, 13(6): 788- 799.
[7] Jiang XH, Zhong RQ, Fan XY,et al. Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroenterol, 2003,9(9):2128-2131.
[8] Liu H, Liu Y, Wang L,et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol, 2010, 10:100.
[9] Lleo A, Jepsen P, Morenghi E, et al. Evolvingtrends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep, 2016,6:25906.
[10] Onofrio FQ, Hirschfield GM, Gulamhusein AF. A practical review of primary biliary cholangitis for the gastroenterologist. Gastroenterol Hepatol (N Y), 2019 ,15(3):145-154.
[11] Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology, 2003,125(5):1476-1479.
[12] 顾而立,姚光弼.中国人原发性胆汁性肝硬化的临床特点:52年文献的系统分析.中华肝脏病杂志,2009,17(11):861-866.
[13] Yamagiwa S, Kamimura H, Takamura M,et al. Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol, 2014,20(10):2606-2612.
[14] Zhang Q, Liu Z, Wu S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Gastroenterol Res Pract, 2019,2019:8959103.
[15] European association for the study of the liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol, 2009,51(2):237-267.
[16] Leung PS, Rossaro L, Davis PA,et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology, 2007, 46(5): 1436–1442.
[17] Yang J, Yu YL, Jin Y,et al. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J Gastroenterol, 2016, 22(33): 7579–7586.
[18] Sebode M, Weiler-Normann C, Liwinski T,et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol, 2018, 9: 609.
[19] Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology, 2017, 65(1):152-163.
[20] Baldo DC, Dellavance A, Ferraz MLG, et al. Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Auto Immun Highl,2019,10(1):10.

体检人群血清M2型抗线粒体抗体流行率调查^*

Prevalence of serum anti-mitochondrial antibody-M2 antibody in health check-up individuals

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查^*[J]. 实用肝脏病杂志, 2022, 25(2): 153-156.
[2]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[3]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[4]	郑小勤, 徐辉, 李丽, 靳华, 汪晓军, 勾春燕. 家族聚集性原发性胆汁性肝硬化患者临床特征分析[J]. 实用肝脏病杂志, 2022, 25(2): 207-210.
[5]	曾议, 李国, 李红翠, 彭雅松, 田峰, 王小军. 熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及对血清Nrf2和HO-1水平的影响[J]. 实用肝脏病杂志, 2022, 25(2): 211-214.
[6]	刘松涛, 刘梅, 渠亚超, 李瑞利, 邵晨, 闾军. 4例原发性肝脏神经内分泌肿瘤临床分析及文献复习[J]. 实用肝脏病杂志, 2022, 25(2): 251-254.
[7]	何福亮, 马琳, 李悦榕, 王宇, 王民, 冯丽娟, 张冠华, 欧晓娟, 刘福全, 贾继东. 非肝硬化性门脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4.
[8]	陈靖, 朱月永. 无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？[J]. 实用肝脏病杂志, 2022, 25(1): 9-12.
[9]	叶超, 李文渊, 李磊, 陈思, 李未, 张开光. 一组不明原因的肝损害患者肝组织病理学诊断研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 38-41.
[10]	周晓永, 白阳秋, 杨惠, 张炳勇, 曲波. 原发性胆汁性胆管炎患者血清甲状腺激素水平和抗甲状腺抗体阳性率变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 46-49.
[11]	李艳乐, 刘笑宇, 姚建宁, 王春峰, 张连峰, 张学秀. 乙型肝炎肝硬化并发肝性脑病患者血氨水平与认知障碍关系研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 74-78.
[12]	谭玉英, 张鑫, 张娟子, 张山西. MRI联合血清GPC3水平鉴别肝脏结节性增生病灶临床应用价值研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 88-91.
[13]	肖倩, 周展, 胡小丽. 肝细胞癌患者肝内病灶超声造影参数变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 92-95.
[14]	陈俊光, 邓晓妃, 林树俊, 雷震. 急性化脓性胆囊炎患者超声影像学特点及其诊断价值^*[J]. 实用肝脏病杂志, 2022, 25(1): 116-119.
[15]	杨帆, 王健, 文智. CT检查对诊断胆囊腺肌症的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(1): 140-143.